Error message

The page you requested does not exist. For your convenience, a search was performed using the query node 94.

Search results

  1. Dr Daniel Munoz-Espin

    My group works at the interface between cellular senescence, plasticity and the fundamental processes and mechanisms that lie at the origin of cancer. We are also developing novel tools and nanodevices for cancer early diagnosis and therapy. ...

  2. Dr Kerstin Meyer

    Genetic Susceptibility to Breast Cancer 1. Functional analysis of predisposition loci: My experiments are aimed at understanding the mechanisms by which breast cancer risk loci contribute to disease risk. This has involved the identification of...

  3. Mr Kourosh Saeb-Parsy

    Immunodeficient mice reconstituted with the human immune compartment (humanised mice), represent an invaluable model to study human cancer biology, as well as the safety and efficacy of cancer immunotherapies. In collaboration with colleagues at the...

  4. Dr Mike Chapman

    Our long-term aim is to understand the interplay between the myriad pathways involved in the pathogenesis of multiple myeloma so that these can be targeted for therapeutic benefit. The initial focus of our research is the role of aberrant RNA processing...

  5. Dr Marc de la Roche

    The molecular aetiology of colorectal cancer (CRC) is well known: the mutant, oncogenic form of the Wnt signaling pathway drives the malignant transformation of intestinal epithelial stem cells leading to tumorigenesis. My primary research interests are...

  6. Dr Quentin Harmer

    ... in lymph nodes - Clinical studies of magnetic sentinel node biopsy - Adjuvant hyperthermia as a cancer treatment - Advanced magnetic ... the need for traditional radioisotopes in sentinel lymph node biopsy (SLNB), improving workflow and costs while increasing availability ...

  7. Dr Peng-Fei Qiu

  8. Professor Antonis Antoniou

    My main research interest is the development and application of statistical modelling techniques for addressing clinical questions, and the development of risk prediction tools which are used in clinical practice. ...

  9. Ms Abigail Colley

  10. Mr Claudio Angione

    Multi-omics metabolic models Optimization

  11. Dr Callum Campbell

  12. Miss Charlotte Simpson

  13. Ms Emily Kate Lythgoe

  14. Dr Flaviu Bulat

  15. Dr Giovanna Mantica

  16. Dr Joanna Krupka

  17. Mr Jamie Huckstep

  18. Impact of Circulating miRNA-371a-3p Test on Appropriateness of Treatment and Cost Outcomes in Patients with Stage I Nonseminomatous Germ Cell Tumors

    ... as adjuvant chemotherapy or primary retroperitoneal lymph node dissection in a patient without cancer. Undertreatment was defined as ... Appropriate treatment decision-making increased from 65% to 94% and 50% to 92% for Stage IA/IB, respectively. The miRNA-based approach ...